Annual report pursuant to Section 13 and 15(d)

Segment Reporting (Details)

v3.7.0.1
Segment Reporting (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Segment Reporting Information [Line Items]    
Revenues - external customers $ 394 $ 948
Revenues - intersegment 0 0
Research and development 4,117 3,156
General and administrative 10,551 7,685
Operating loss (14,274) (9,893)
Interest expense (1,929) (807)
Interest and other income 64 43
Consolidated net loss (16,139) (10,657)
Total assets 36,010 51,600
Fixed assets, net 25,589 25,574
Intangible assets, net 1,823 2,092
Depreciation expense 1,326 577
Amortization of intangible assets 350 363
Intersegment Eliminations [Member]    
Segment Reporting Information [Line Items]    
Revenues - external customers 0 0
Revenues - intersegment (2,252) (482)
Research and development (1,303) (329)
General and administrative (949) (153)
Operating loss 0 0
Interest expense 0 0
Interest and other income 0 0
Consolidated net loss 0 0
Total assets (12,777) (75)
Fixed assets, net 0 0
Intangible assets, net 0 0
Depreciation expense 0 0
Amortization of intangible assets 0 0
iBio CDMO [Member] | Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Revenues - external customers 123 55 [1]
Revenues - intersegment 1,280 324 [1]
Research and development 1,763 501 [1]
General and administrative 6,255 2,278 [1]
Operating loss (6,615) (2,400) [1]
Interest expense (1,928) (807) [1]
Interest and other income 21 10 [1]
Consolidated net loss (8,522) (3,197) [1]
Total assets 29,738 38,282 [1]
Fixed assets, net 25,581 25,566 [1]
Intangible assets, net 0 0 [1]
Depreciation expense 1,323 573 [1]
Amortization of intangible assets 0 0 [1]
iBio, Inc [Member] | Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Revenues - external customers 271 893
Revenues - intersegment 972 158
Research and development 3,657 2,984
General and administrative 5,245 5,560
Operating loss (7,659) (7,493)
Interest expense (1) 0
Interest and other income 43 33
Consolidated net loss (7,617) (7,460)
Total assets 19,049 13,393
Fixed assets, net 8 8
Intangible assets, net 1,823 2,092
Depreciation expense 3 4
Amortization of intangible assets $ 350 $ 363
[1] iBio CDMO commenced operations in December 2015.